Third-Party Oversight Of Device Changes Urged In Formal Complaint
This article was originally published in The Gray Sheet
Executive Summary
FDA should amend its policy on device modifications to require their review by an independent third party, or the agency itself, prior to marketing, according to a Jan. 14 formal complaint